Mesoblast Ltd - Asset Resilience Ratio

Latest as of June 2023: 0.00%

Mesoblast Ltd (MSB) has an Asset Resilience Ratio of 0.00% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check Mesoblast Ltd (MSB) strategic asset index to assess the company's strategic physical and investment asset allocation.

Liquid Assets

AU$-2.00K

≈ $-1.42K USD Cash + Short-term Investments

Total Assets

AU$669.41 Million

≈ $473.65 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2013–2023)

This chart shows how Mesoblast Ltd's Asset Resilience Ratio has changed over time. See how leveraged is Mesoblast Ltd's balance sheet to measure how much of total assets are equity-financed.

Liquid Assets Composition Over Time

This chart breaks down Mesoblast Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Mesoblast Ltd (MSB) total market value.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	AU$-2.00K	-0.0%
Short-term Investments	AU$0.00	0%
Total Liquid Assets	AU$-2.00K	0.00%

Asset Resilience Insights

Limited Liquidity: Mesoblast Ltd maintains only 0.00% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Mesoblast Ltd Industry Peers by Asset Resilience Ratio

Compare Mesoblast Ltd's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
CSL Ltd AU:CSL	Biotechnology	0.41%
BB Biotech AG SW:BION	Biotechnology	0.05%
Concord Biotech Limited NSE:CONCORDBIO	Biotechnology	18.00%
Pharming Group NV AS:PHARM	Biotechnology	7.13%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Clarity Pharmaceuticals Ltd AU:CU6	Biotechnology	73.99%
Yantai Zhenghai Bio-Tech Co Ltd SHE:300653	Biotechnology	56.48%

Annual Asset Resilience Ratio for Mesoblast Ltd (2013–2023)

The table below shows the annual Asset Resilience Ratio data for Mesoblast Ltd.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2023-06-30	0.00%	AU$-2.00K ≈ $-1.42K	AU$669.41 Million ≈ $473.65 Million	0.00pp
2022-06-30	0.00%	AU$13.00K ≈ $9.20K	AU$662.14 Million ≈ $468.51 Million	+0.01pp
2021-06-30	-0.01%	AU$-49.00K ≈ $-34.67K	AU$744.72 Million ≈ $526.93 Million	-0.01pp
2020-06-30	0.00%	AU$12.00K ≈ $8.49K	AU$733.60 Million ≈ $519.07 Million	0.00pp
2019-06-30	0.00%	AU$21.00K ≈ $14.86K	AU$652.12 Million ≈ $461.41 Million	-0.05pp
2018-06-30	0.06%	AU$392.00K ≈ $277.36K	AU$692.44 Million ≈ $489.95 Million	-5.71pp
2017-06-30	5.76%	AU$37.79 Million ≈ $26.74 Million	AU$655.69 Million ≈ $463.94 Million	+5.40pp
2013-06-30	0.36%	AU$3.19 Million ≈ $2.26 Million	AU$883.71 Million ≈ $625.28 Million	--

pp = percentage points

About Mesoblast Ltd

AU:MSB Australia Biotechnology

Market Cap

$1.95 Billion

AU$2.75 Billion AUD

Market Cap Rank

#6400 Global

#148 in Australia

Share Price

AU$2.13

Change (1 day)

+3.40%

52-Week Range

AU$1.57 - AU$3.07

All Time High

AU$5.21